# Perioperative Outcomes With Direct Oral Anticoagulants in Orthopaedic Trauma Surgery: A Systematic Review and Meta-Analysis

**Authors:** Olive Kyaw, Chan Khin

PMC · DOI: 10.7759/cureus.97688 · Cureus · 2025-11-24

## TL;DR

This study compares outcomes of using direct oral anticoagulants in orthopedic trauma surgery and finds they are safe but may cause minor surgical delays.

## Contribution

The study provides a systematic review and meta-analysis of DOAC use in orthopedic trauma surgery, addressing clinical outcomes and management strategies.

## Key findings

- DOAC use was not associated with increased mortality, transfusion, or venous thromboembolism.
- DOAC users experienced a modest increase in surgical delay beyond 24-36 hours.
- Early fixation without routine reversal appears safe when renal function is adequate and no active bleeding exists.

## Abstract

The perioperative management of direct oral anticoagulants (DOACs) in orthopaedic trauma is variably practised. We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-concordant systematic review and meta-analysis of adult trauma surgery comparing DOAC exposure with vitamin K antagonists or no anticoagulation. MEDLINE, Embase, and CENTRAL were searched (2010-October 2025) for randomised and observational studies. Pre-injury DOAC use informed analyses of mortality, transfusion, and operative delay, whereas postoperative prophylaxis trials addressed venous thromboembolism (VTE); these represent two distinct clinical questions that were analysed separately. Risk of bias (Risk of Bias 2/Risk of Bias in Non-randomized Studies - of Interventions), random-effects pooling, and GRADE were used. In total, 15 studies (4 randomised, 11 observational; >6,000 patients) were included. DOAC exposure was not associated with higher mortality (risk ratio (RR) = 0.98, 95% confidence interval (CI) = 0.66-1.45), transfusion (RR = 1.20, 95% CI = 0.96-1.49), or VTE (RR = 0.41, 95% CI = 0.16-1.05). DOAC users more often experienced operative delay beyond 24-36 hours (RR = 2.43, 95% CI = 0.93-6.33), which may reflect institutional caution. Evidence certainty ranged from low to moderate. In orthopaedic trauma, DOAC use is not linked to increased perioperative bleeding, transfusion, VTE, or mortality, but is associated with modest surgical delay. Where renal function is adequate and no active bleeding exists, early fixation without routine pharmacological reversal appears safe. Standardised early-surgery pathways and education on DOAC pharmacokinetics may reduce avoidable delays.

## Linked entities

- **Diseases:** venous thromboembolism (MONDO:0005399)

## Full-text entities

- **Diseases:** VTE (MESH:D054556), Trauma (MESH:D014947), bleeding (MESH:D006470)
- **Chemicals:** DOAC (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12643575/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12643575/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12643575/full.md

---
Source: https://tomesphere.com/paper/PMC12643575